Earnings Summary

Protagonist Therapeutics Inc’s revenue jumped +Inf% since last year same period to $254.95Mn in the Q1 2024. On a quarterly growth basis, Protagonist Therapeutics Inc has generated 324.92% jump in its revenue since last 3-months.

Protagonist Therapeutics Inc’s net profit jumped 759.71% since last year same period to $207.34Mn in the Q1 2024. On a quarterly growth basis, Protagonist Therapeutics Inc has generated 658.51% jump in its net profits since last 3-months.

Protagonist Therapeutics Inc’s net profit margin jumped NaN% since last year same period to 81.32% in the Q1 2024. On a quarterly growth basis, Protagonist Therapeutics Inc has generated 78.51% jump in its net profit margins since last 3-months.

Protagonist Therapeutics Inc’s price-to-earnings ratio after this Q1 2024 earnings stands at 16.55.

Protagonist Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.6 - a -150.42% fall from last quarter’s estimates.

Protagonist Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.6.

Protagonist Therapeutics Inc’s earning per share (EPS) jumped 586.57% since last year same period to 3.26 in the Q1 2024. This indicates that the Protagonist Therapeutics Inc has generated 586.57% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Protagonist Therapeutics Inc’s return on assets (ROA) stands at 0.21.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Protagonist Therapeutics Inc’s return on equity (ROE) stands at 0.42.